(Q36964732)

17 August 2017

1 reference

title

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies (English)

1 reference

17 August 2017

4

Kenneth C Anderson

1 reference

17 August 2017

Klaus Podar

1

1 reference

17 August 2017

Marc S Raab

series ordinal

2

1 reference

17 August 2017

Dharminder Chauhan

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

1693-1707

1 reference

Characterization of a specific phorbol ester aporeceptor in mouse brain cytosol

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Discovery and prospect of protein kinase C research: epilogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Competitive inhibition by diacylglycerol of specific phorbol ester binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C and other diacylglycerol effectors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Targeting the protein kinase C family: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C is regulated in vivo by three functionally distinct phosphorylations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Phosphorylation of threonine 638 critically controls the dephosphorylation and inactivation of protein kinase Calpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Identification of in vivo phosphorylation sites required for protein kinase D activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Localization of protein kinases by anchoring proteins: a theme in signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Identification of PKC-isoform-specific biological actions using pharmacological approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Studies and perspectives of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The Albert Lasker Medical Awards. The family of protein kinase C for signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C, calcium and phospholipid degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C--a question of specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Regulation of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C-mediated regulation of the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C: a novel target for inhibiting gastric cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Differential expression of protein kinase C isoenzymes related to high nitric oxide synthase activity in a T lymphoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Abnormal behavior of protein kinase C in the human myeloma cell line, RPMI 8226.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C-delta is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Wnts induce migration and invasion of myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The link between PKCalpha regulation and cellular transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21(waf1/cip1) and p27(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The alpha isoform of protein kinase C mediates phorbol ester-induced growth inhibition and p21cip1 induction in HC11 mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C alpha activates RAF-1 by direct phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase Calpha promotes apoptotic cell death in gastric cancer cells depending upon loss of anchorage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

PKCalpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Site-directed perturbation of protein kinase C- integrin interaction blocks carcinoma cell chemotaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Overproduction of protein kinase C causes disordered growth control in rat fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C-beta as a therapeutic target in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Inactivation of DNA-dependent protein kinase by protein kinase Cdelta: implications for apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase Cdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Suppression of apoptosis in the protein kinase Cdelta null mouse in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Phorbol ester-induced G1 phase arrest selectively mediated by protein kinase Cdelta-dependent induction of p21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase Cdelta inhibition of S-phase transition in capillary endothelial cells involves the cyclin-dependent kinase inhibitor p27(Kip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

PKCdelta acts as a growth and tumor suppressor in rat colonic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Increased protein kinase C delta in mammary tumor cells: relationship to transformtion and metastatic progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase Cepsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Failure of wild-type or a mutant form of protein kinase C-alpha to transform fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein kinase C inhibitors as novel anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Antiangiogenic effects of a protein kinase Cbeta-selective small molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The clinical development of the bryostatins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Antitumor compounds from tunicates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Preclinical and clinical development of novel agents that target the protein kinase C family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Characterization of the interaction of ingenol 3-angelate with protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Proceedings of the First International Conference on PEP005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Cancer chemoprevention with dietary phytochemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Biological effects of curcumin and its role in cancer chemoprevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Pharmacokinetics and pharmacodynamics of curcumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Biological properties of curcumin-cellular and molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Multiple biological activities of curcumin: a short review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Therapeutic potential of natural compounds that regulate the activity of protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

PKC-δ is an apoptotic lamin kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

Protein Kinase C δ Inhibits the Proliferation of Vascular Smooth Muscle Cells by Suppressing G1Cyclin Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

The role of protein kinase C in cell surface signal transduction and tumour promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1693

10.1517/13543784.16.10.1693

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference